department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Lokelma · pharmadog

pharmadog
drugs
Lokelma

drug

patient view →

sodium zirconium cyclosilicate

Marketedupdated 2mo ago

by AstraZeneca Pharmaceuticals LP

Approved

community read0 votes

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Lokelma

generic

sodium zirconium cyclosilicate

indication

Hyperkalemia

phase

marketed

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Patent cliff

source: FDA Orange Book

first barrier falls

Feb 10, 2032

~5.6 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (27)

Oct 14, 2035compositionUS 10300087
Oct 14, 2035compositionUS 10300087
Oct 14, 2035method-of-use (U-2312)US 11738044
Oct 14, 2035method-of-use (U-2312)US 11738044
Oct 14, 2035compositionUS 9592253
Oct 14, 2035compositionUS 9592253
Oct 22, 2033compositionUS 10695365
Oct 22, 2033compositionUS 10695365
Oct 22, 2033compositionUS 8877255
Oct 22, 2033compositionUS 8877255
Oct 22, 2033compositionUS 9913860
Oct 22, 2033compositionUS 9913860
Apr 19, 2032compositionUS 8802152
Apr 19, 2032compositionUS 8802152
Feb 10, 2032method-of-use (U-2312)US 10335432
Feb 10, 2032method-of-use (U-2312)US 10398730
Feb 10, 2032method-of-use (U-2312)US 10398730
Feb 10, 2032compositionUS 10413569
Feb 10, 2032compositionUS 10413569
Feb 10, 2032compositionUS 11406662
Feb 10, 2032compositionUS 11406662
Feb 10, 2032method-of-use (U-2312)US 8808750
Feb 10, 2032method-of-use (U-2312)US 8808750
Feb 10, 2032method-of-use (U-2312)US 9844567
Feb 10, 2032method-of-use (U-2312)US 9844567
Feb 10, 2032method-of-use (U-2312)US 9861658
Feb 10, 2032method-of-use (U-2312)US 9861658

Data sources

ClinicalTrials.gov

last refreshed 1h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Trials studying sodium zirconium cyclosilicate

phase3An Open-label Study to Assess Safety and Efficacy of SZC in Paediatric Patients With Hyperkalaemiarecruitingn=140
phase3A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemiaterminatedn=1,112
—A National, Multicenter, Prospective, Observational Study to Assess Patient Characteristics, Treatment Algorithms and Disease Management of Hyperkalaemia Patients With Chronic Kidney Disease or Under Dialysis or With Heart Failure, Treated With Sodium Zirconium Cyclosilicate in Greececompletedn=125
phase4Continuing Sodium Zirconium Cyclosilicate (SZC) After Discharge Studycompletedn=186
phase4Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving Spironolactonecompletedn=366
phase2OPtimizing Aldosterone Receptor Antagonist Therapy by Sodium Zirconium Cyclosilicate in Heart Failureactive not recruitingn=110
phase3Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes)terminatedn=2,690
phase3A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia.completedn=270

more trials →